Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02532907 · ClinicalTrials.gov registry record
Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs
A clinical trial, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- 5
- Enrollment target
NCT02532907: Completed study, sponsored by University of Colorado, Denver.
NCT02532907 is a clinical trial that has completed, run by University of Colorado, Denver. The registered enrollment target is 5 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02532907 has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- 5 participants
- Enrollment target
Study Summary
This study is designed to obtain and store samples of serum and liver tissue in HCV (HepC Virus)-infected patients being treated with direct-acting antiviral (DAA) therapy, and to determine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood. The introduction of new DAAs regimens that do not include IFN provides unique and novel opportunities to examine whether successful treatment-induced eradication of viral antigen results in reconstitution of T cell immunity. serum and liver tissue samples will be collected and stored in hopes of improving treatment and outcomes for future patients.
Primary Outcome
To examine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood.
Interventions
- PROCEDURE Liver Biopsy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-08 |
| Est. Completion | 2018-07-10 |
What the finished NCT02532907 record still lists
NCT02532907 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 5 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Liver Biopsy is the first listed.
NCT02532907 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02532907 about?
NCT02532907 is a clinical study titled "Study of Hepatic Responses in Patients Receiving Direct-acting Anti-HCV Drugs". This study is designed to obtain and store samples of serum and liver tissue in HCV (HepC Virus)-infected patients being treated with direct-acting antiviral (DAA) therapy, and to determine the effect of new DAA therapies on HCV-related responses in the liver and peripheral blood. The introduction ...
What is the current status of trial NCT02532907?
This trial is currently completed. The enrollment target is 5 participants. The study started on 2015-08. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT02532907?
The interventions under investigation include: Liver Biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT02532907?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia